A single unnamed patient has found himself at the centre of a political and medical storm after gaining rare early access to one of the world's most anticipated obesity treatments.
The controversy erupted when reports revealed that a 79-year-old man received Eli Lilly's experimental drug retatrutide through the US Food and Drug Administration's compassionate use programme, a pathway normally reserved for patients with serious or life-threatening conditions.
